Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 15/20 | 0.63 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 4/20 | 0.33 |
| ▸ | JAK1 | P23458 | 4/20 | 0.33 |
| ▸ | TYK2 | P29597 | 4/20 | 0.33 |
| ▸ | JAK3 | P52333 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22644593 | 1.00 | RIPK1 (0.63) | RIPK1GPR119JAK2JAK1TYK2 | |
| SCHEMBL22644588 | 1.00 | RIPK1 (0.63) | RIPK1GPR119JAK2JAK1TYK2 | |
| SCHEMBL22644592 | 1.00 | RIPK1 (0.63) | RIPK1GPR119JAK2JAK1TYK2 | |
| SCHEMBL30968269 | 1.00 | RIPK1 (0.63) | RIPK1GPR119JAK2JAK1TYK2 | |
| SCHEMBL22638799 | 1.00 | RIPK1 (0.63) | RIPK1GPR119JAK2JAK1TYK2 | |
| SCHEMBL22644569 | 0.93 | RIPK1 (0.74) | RIPK1GPR119JAK2JAK1TYK2 | |
| SCHEMBL22638856 | 0.87 | RIPK1 (0.46) | RIPK1JAK2JAK1TYK2JAK3 | |
| SCHEMBL22638933 | 0.87 | RIPK1 (0.58) | RIPK1 | |
| SCHEMBL30968230 | 0.87 | RIPK1 (0.58) | RIPK1 | |
| SCHEMBL20165926 | 0.86 | RIPK1 (0.85) | RIPK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220235032-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2022-07-28 | — | — | US | disclosed |
| EP-3967682-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020224656-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235032-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | RIPK1 1/4885GPR119 999/4885JAK2 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.